Serum concentration of asprosin in new-onset type 2 diabetes

Serum concentration of asprosin in new-onset type 2 diabetes

Asprosin, a newly identified adipokine, is pathologically increased in individuals with insulin resistance. However, the available evidence on the association of asprosin and type 2 diabetes mellitus (T2DM) status is still scarce. Therefore, this study aimed to determine the relationship between ser...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetology and metabolic syndrome 2020-07, Vol.12 (1), p.65-8, Article 65
Hauptverfasser: Naiemian, Shakiba, Naeemipour, Mohsen, Zarei, Mehdi, Lari Najafi, Moslem, Gohari, Ali, Behroozikhah, Mohammad Reza, Heydari, Hafez, Miri, Mohammad
Format: Artikel
Sprache:eng
Schlagworte:
Adipokine
Analysis
Arteriosclerosis
Asprosin
Blood glucose
Blood pressure
Body mass index
Cardiac patients
Cardiovascular diseases
Cholesterol
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Enzyme-linked immunosorbent assay
Enzymes
Glucose
Glycosylated hemoglobin
Hemoglobin
High density lipoprotein
Hypertension
Insulin
Insulin resistance
Lipids
Obesity
Risk factors
Software
Type 2 diabetes
Variance analysis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Asprosin, a newly identified adipokine, is pathologically increased in individuals with insulin resistance. However, the available evidence on the association of asprosin and type 2 diabetes mellitus (T2DM) status is still scarce. Therefore, this study aimed to determine the relationship between serum concentrations of asprosin and T2DM status. This observational study was performed based on 194 adults (97 newly diagnosed T2DM and 97 healthy individuals). Anthropometric and biochemical variables were determined in all participants. Serum concentrations of asprosin were measured using enzyme-linked immunosorbent assay (ELISA). In patients with T2DM, the serum concentrations of asprosin were significantly higher than the healthy controls (4.18 [IQR: 4.4] vs. 3.5 [IQR: 1.85], P 
ISSN:1758-5996
1758-5996
DOI:10.1186/s13098-020-00564-w